课题基金 / 基金详情

项目摘要

项目成果

JEFFREY Victor RAVETCH的其他基金

相似基金

相关文献

中文摘要
翻译
最近的研究强调了Fc-FCR相互作用对实现体内保护的重要性 通过ADCC和ADCC等机制中和HIV和其他病毒或细菌毒素的抗体 ADCVL.我们已经定义了Ig G Fc与FcγRs结合所需的氨基酸和多糖 基于新品系的FcγR人源化小鼠建立动物模型以确定氨基酸的影响 人免疫球蛋白的酸和多糖修饰对其体内功能的影响。尽管越来越多的人对 Fc介导的效应器功能对抗体介导的病毒体内效力的重要性 对于bNAbs对HIV的中和,还没有进行系统的研究来确定最佳的Fc 将导致这些活动的结构。我们将表征Fc结构和效应器的贡献 对Nussenzweig分离的bNAbs的活性的影响,并产生优化的修饰bNAbs FC效应器函数。这些重新设计的bNAbs将在体外进行中和、ADCC和 ADCVBI和与Nussenzweig合作,在一种基于TZM-bl的新的体内中和试验中 在携带人FcγR的小鼠中进行检测。与比约克曼合作,我们将获得 这些修饰的抗体Fc单独或与特定的FcγR复合,这些数据将指导产生 额外的变种,进一步增强FC-FCγR功能。这些研究将导致产生 新颖的bNAbs,针对中和和效应器功能进行了优化,并提供了开发框架 免疫策略将导致bNAbs具有最佳的效应器特性。
英文摘要
Recent studies have highlighted the significance of Fc-FcR interactions to achieve in vivo protection for neutralizing antibodies to HIV and other viruses or bacterial toxins through mechanisms including ADCC and ADCVl. We have defined both the amino acid and glycan requirements for IgG Fc binding to FcγRs and developed animal models based on novel strains of FcγR humanized mice to determine the impact of amino acid and glycan modifications of human IgGs on their in vivo function. Despite the growing appreciation for the importance of Fc mediated effector functions to the in vivo potency of antibody mediated viral neutralization for bNAbs to HIV, no systematic studies have been performed to determine the optimal Fc structure that will result in these activities. We will characterize the contributions of Fc structure and effector functions to the activities of the bNAbs isolated by Nussenzweig and generate modified bNAbs optimized for Fc effector functions. These re-engineered bNAbs will be tested in vitro for neutralization, ADCC and ADCVBI and, in collaboration with Nussenzweig, in a novel in vivo neutralization assay, based on the TZM-bl assay in mice that carry human FcγR. In collaboration with Bjorkman we will obtain structural information for these modified antibody Fc's, alone and in complex to specific FcγRs, These data will direct the generation of additional variants to further enhance Fc-FcγR function. These studies will result in the generation of novel, bNAbs optimized for both neutralization and effector function and provide the framework to develop immunization strategies that will result in bNAbs with optimal effector properties.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project-003
  • 批准号:
    10170029
  • 项目类别:
  • 资助金额:
    $62.61万
  • 财政年份:
    2020
  • 负责人:
    JEFFREY Victor RAVETCH
  • 依托单位:
Integrating innate and adaptive pathways in vaccine responses
  • 批准号:
    10265794
  • 项目类别:
  • 资助金额:
    $150.0万
  • 财政年份:
    2020
  • 负责人:
    JEFFREY Victor RAVETCH
  • 依托单位:
Project-002
  • 批准号:
    10169069
  • 项目类别:
  • 资助金额:
    $87.39万
  • 财政年份:
    2020
  • 负责人:
    JEFFREY Victor RAVETCH
  • 依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
  • 批准号:
    10368931
  • 项目类别:
  • 资助金额:
    $99.67万
  • 财政年份:
    2016
  • 负责人:
    JEFFREY Victor RAVETCH
  • 依托单位:
海外基金